ea0090rc8.5 | Rapid Communications 8: Calcium and Bone | ECE2023
Istvan Takacs
, Mezozi Emese
, Soto Alfonso
, Kamenicky Peter
, Figueres Lucile
, Angeles Galvez Moreno M.
, Lemoine Sandrine
, Borson-Chazot Francoise
, Capel Ismael
, Ovize Michel
, OuldRouis Taha
, Allas Soraya
, Sumeray Mark
, Mannstadt Michael
Background: Conventional therapy for chronic hypoparathyroidism (cHP) is often unable to maintain stable normal serum calcium (Ca) levels for a full 24 h, to control symptoms, to prevent the detrimental long-term effects on the kidney and to preserve normal bone architecture. Eneboparatide (AZP-3601) is a novel 36-amino-acid peptide specifically designed to activate the R0 conformation of the PTH receptor 1, that results in a prolonged calcemic response and a sustai...